National Jewish Health is the leading respiratory hospital in the nation. Founded 125 years ago as a nonprofit hospital, National Jewish Health today is the only facility in the world dedicated exclusively to groundbreaking medical research and treatment of patients with respiratory and complex diseases. Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care. To learn more, visit njhealth.org.
National Jewish Health Advanced Diagnostic Laboratories
National Jewish Health Advanced Diagnostic Laboratories provides unparalleled expertise in immune and respiratory disease to our clinical, biotech, pharmaceutical, public health and diagnostic partners. Our high complexity, CLIA and CAP15189-certified laboratories have decades of experience developing immunology, complement, infectious disease and molecular genomic tests. Our world-renowned scientists are committed to providing the highest quality specialized laboratory services. Visit us at Booth 1026 to learn about our TRIKAFTKA drug monitoring test, Alpha-1 genomic panel and more. Njlabs.org
National Disease Research Interchange (NDRI)
For 40 years, National Disease Research Interchange has revolutionized the progress of scientific research by partnering with organ and tissue donation programs to procure and distribute human biospecimens to biomedical researchers. The National Institutes of Health has provided funding to NDRI since 1987. Partnering for Progress Researchers in academic medical centers, non-profit research organizations, as well as pharmaceutical, biotechnology, and medical device companies rely on NDRI for access to quality human biospecimens.
Keenova Therapeutics
Keenova Therapeutics is a leading global developer and manufacturer of branded therapeutics that strives to help patients with rare or unaddressed conditions live happier and healthier lives. | At Keenova, we believe that no one should be alone in their pursuit of better health. This purpose drives us as we pair quality therapeutics with human support—showing up in big moments and small to help patients find comfort and confidence. We bring deep expertise and resolve to every therapeutic area we serve, including immunology, urology, orthopedics, critical care, and pediatric endocrinology. We work with patients, care partners, and physicians to help them navigate healthcare system complexity and access therapies that make a meaningful difference. We are Keenova—keen to solve, keen to serve. Learn more at www.keenova.com. | Keenova Therapeutics is a leading global developer and manufacturer of branded therapeutics that strives to help patients with rare or unaddressed conditions live happier and healthier lives. The Company’s diversified brands portfolio is focused across a wide range of therapeutic areas of significant unmet need, including endocrinology, gastroenterology, hepatology, immunology, neonatal respiratory critical care, nephrology, neurology, pulmonology, ophthalmology, orthopedics, rheumatology and urology. Globally headquartered in Dublin, Ireland, Keenova benefits from a strong U.S. manufacturing footprint with facilities in Louisiana, New Jersey, New York, Pennsylvania and Wisconsin. To learn more, please visit www.keenova.com.
Intuitive Surgical
At Intuitive®, innovating for minimally invasive care is the passion that drives us. Our robotic-assisted da Vinci® Surgical System helps empower doctors and hospitals to make surgery less invasive than an open approach. | At Intuitive®, innovating for minimally invasive care is the passion that drives us. The Ion endoluminal system is Intuitive’s robotic-assisted platform for minimally invasive biopsy in the lung. We built Ion on the belief that collecting lung tissue samples for biopsy could be safe and simple, even when nodules are small and located in the peripheral lung. Ion’s ultrathin, ultramaneuverable catheter allows clinicians to reach small lesions in all 18 segments of the lung.
Insmed
Insmed is a global biopharmaceutical company dedicated to the development of treatments for serious and rare diseases. We have more than 700 employees throughout the U.S., Europe, and Japan, and we continue to build our global infrastructure and organizational capabilities. Our five core values—collaboration, accountability, passion, respect, and integrity—set the tone for our culture and guide the actions we take each day. | Insmed Incorporated is a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases. Insmed is advancing a diverse portfolio of approved and mid- to late-stage investigational medicines as well as cutting-edge drug discovery focused on serving patient communities where the need is greatest. Insmed’s most advanced programs are in pulmonary and inflammatory conditions. Headquartered in Bridgewater, New Jersey, Insmed has offices and research locations throughout the United States, Europe, and Japan. Visit www.Insmed.com to learn more.
Hyfe
Hyfe is the global leader in providing continuous, passive cough monitoring as an endpoint for clinical trials and research. Hyfe’s CoughMonitor Suite is a smartwatch-based solution used in numerous regulatory-focused drug development trials, from proof of concept to Phase 3 studies, as an exploratory or primary endpoint across therapeutic areas including refractory chronic cough, bronchiectasis, COPD, and more. Hyfe’s CoughMonitor Suite is a validated, accurate, and fully privacy-preserving solution for continuous cough monitoring. Hyfe’s cough monitoring has been used in over 50 research trials and has resulted in over 20 peer-reviewed publications spanning more than 18 therapeutic indications. Hyfe is also developing an evidence-based digital therapeutic (DTx) solution for cough hypersensitivity, which recently reported over a 40% reduction in cough frequency over 4 weeks. Hyfe’s DTx is already licensed for development as a prescription DTx in Japan, and Hyfe is actively seeking partners to address cough hypersensitivity as a treatable trait of respiratory conditions (e.g., asthma, among others) in other global markets.
Hermansky-Pudlak Syndrome Network, Inc.
Our Mission is to provide education and vital support programs to individuals and families with Hermansky-Pudlak syndrome while striving for improved care and innovative research on our journey to cureHPS. We are a 501c3 non-profit organization founded in 1992 and incorporated in 1995. To achieve this goal, the HPS Network gathers and disseminates information, promotes awareness, funds research, and provides support to our members.